Ankylosing Spondylitis, Arthritis, Psoriatic, Rheumatoid Arthritis
Conditions
Keywords
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, golimumab, anti-TNF biologics, non-anti-TNF biologics, non-biological treatments
Brief summary
The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan.The objective of this study is to estimate the rate of serious infections, tuberculosis, malignancies, and other outcomes in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients treated with golimumab, anti-tumor necrosis factor (TNF) biologics, non-anti-TNF biologics, or systemic non-biological treatments.
Detailed description
The participants included in this study will be drawn from the Ingenix Normative Health Informatics Database, a proprietary research database containing claims and enrollment data dating back to 1993 for members of a large, geographically diverse US health plan. This study will include cohorts of participants who have claims consistent with a diagnosis of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis and who initiate golimumab, anti-TNF biologics, non-anti-TNF biologics, or systemic non-biological treatments. Participants will be identified by claims bearing codes for dispensed drugs, procedures or diagnoses and followed after the launch of golimumab for up to 8 years. A sample of enrolled health plan members without claims evidence of diagnosis or treatment of Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis will also be selected. The claims database will be used to estimate the incidence of the primary outcomes of serious infections, tuberculosis (TB) and non-TB mycobacterial infections, malignancies such as lymphoma, and other selected outcomes. No study agents will be administered in this study. All participants will receive standard-of-care treatment as prescribed by their physician
Interventions
as prescribed
BIOLOGICALanti-TNF biologics
as prescribed
BIOLOGICALgolimumab
as prescribed
BIOLOGICALnon-anti-TNF biologics
as prescribed
OTHERgeneral population
non-treated cohort
Sponsors
Janssen Biotech, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Complete medical coverage and pharmacy benefits * Six months of continuous enrollment prior to the date of cohort entry
Exclusion criteria
* Participants will be excluded if they do not have information on age, gender or enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimate incidence of serious infections, malignancies, and other selected outcomes in patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis initiating golimumab and other biological and systemic non-biological treatment | The study will be approximately 8 years in duration |
Outcome results
None listed